Keywords: Myocardium, Cardiomyopathy
Motivation: In the 2020 AHA/ACC guideline for patients with hypertrophic cardiomyopathy (HCM), repeat contrast-enhanced cardiac magnetic resonance (CMR) is recommended to evaluate late gadolinium enhancement (LGE) changes every 3-5 years for risk stratification.
Goal(s): To investigate the prognostic value of LGE assessed by serial CMR in HCM patients.
Approach: 313 consecutive patients with HCM who underwent two CMRs with long-term follow-up were retrospectively included.
Results: On the MaxStat analysis for primary and secondary endpoints, the optimal prognostic cut point was >1.50 and 3.75g/year, respectively. LGE mass progression was independently associated with the outcome and further improve the risk stratification.
Impact: In patients with hypertrophic cardiomyopathy, myocardial fibrosis increases over time. Judicious and serial assessments of late gadolinium enhancement on cardiac magnetic resonance can improve risk stratification and clinical decision-making to help patient management.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords